Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study-Reference-Cited by-同舟云学术

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study

Published:2021-01-20 Issue:2 Volume:4 Page:
ISSN:2398-9238
Container-title:Endocrinology, Diabetes & Metabolism
language:en
Short-container-title:Endocrino Diabet & Metabol

Author:

Ji Linong¹^ORCID,Li Ling²,Ma Jianhua³,Li Xuefeng⁴,Li Dongmei⁵,Meng Bangzhu⁶,Lu Weiping⁷,Sun Jiao⁸,Liu Yanmei⁹,Takayanagi Gen¹⁰,Wang Yi¹¹^ORCID

Affiliation:

1. Peking University People's Hospital Beijing China

2. Shengjing Hospital of China Medical University Liaoning China

3. Nanjing First Hospital Nanjing Jiangsu China

4. Shiyan Taihe Hospital Hubei China

5. Inner Mongolia People’s Hospital Inner Mongolia China

6. The Affiliated Hospital of Inner Mongolia University for Nationalities Inner Mongolia China

7. Huai'an First People’s Hospital Nanjing Medical University Nanjing Jiangsu China

8. Huadong Hospital Affiliated to Fudan University Shanghai China

9. Yancheng City No.1 People's Hospital Jiangsu China

10. Mitsubishi Tanabe Pharma Development America, Inc. Jersey City NJ USA

11. Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd. Beijing China

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/edm2.222

Reference33 articles.

1. Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication

2. Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY

3. Standards of medical care for type 2 diabetes in China 2019

4. Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)

5. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis;Frontiers in Endocrinology;2023-12-18

2. Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study;Expert Review of Endocrinology & Metabolism;2023-12-11

3. Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study;Expert Review of Endocrinology & Metabolism;2023-05-26

4. Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes;Journal of Endocrinological Investigation;2023-01-09

5. Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects;Expert Review of Clinical Pharmacology;2023-01-02